Develops machine learning-enabled thymic cell therapies to restore immune function for immunodeficiencies, transplants, and autoimmune diseases.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Overview
Thymmune is a biotechnology company developing a machine learning-enabled thymic cell engineering platform to restore normal immune function in aging and disease. The company’s cutting-edge approach in iPSC-thymic cell manufacturing can generate off-the-shelf cells at scale. The company is developing a pipeline of therapies to treat immunodeficiencies, transplant related, and autoimmune diseases.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Thymmune Therapeutics Management Team
Investors
NYBC Ventures
Pillar VC
Thymmune Therapeutics Valuations & Financials
View real-time NPM data on Thymmune Therapeutics stock including daily Thymmune Therapeutics stock price estimates, valuation history, and historical share price information. Access Thymmune Therapeutics financing rounds, secondary trade levels, cap table data, and private company comparable transactions. Use NPM's private company valuation database to track Thymmune Therapeutics pricing across six independent market signals. Looking for private company due diligence data sources on Thymmune Therapeutics? Get in touch to learn more.
Similar Companies
like Thymmune Therapeutics
Podium
Enterprise Software
Customer messaging platform enabling companies to connect at critical touch points.
Reality Defender
Cybersecurity
Offers a platform that detects AI-generated media across multiple formats, enabling organizations to secure communications and prevent fraudulent activities.
KINS
Manages a hybrid medical framework to coordinate virtual and in-home orthopedic rehabilitation therapy.
Bite
Commerce & Marketplaces
Provides AI-driven self-ordering kiosks that personalize the dining experience, boosting sales and operational efficiency.
Blue Origin
Designs, builds, and operates rocket engines, launch vehicles, lunar landers, and satellite systems.
Siren Biotechnology
Healthcare & Life Sciences
Activating how solid tumors are targeted by harnessing vectorized cytokines that ignite immune attack with precision and inherent safety.
Forge Nano
Develops ultra-thin atomic coatings and manufactures advanced battery cells to enhance performance in energy, semiconductor, and defense sectors.
Zuub
Healthcare & Life Sciences
Empowers dental practices with AI automation that simplifies insurance checks and streamlines treatment planning for clearer workflows.
HALARA
A women's fashion brand that blends activewear-inspired fabrics with everyday designs, offering versatile clothing options for various occasions.
FAQ
We have answers
Thymmune Therapeutics stock does not trade on public stock exchanges. Thymmune Therapeutics stock is considered a private security and you need to be an accredited investor to trade shares. To invest in Thymmune Therapeutics stock you can either buy shares directly through the company or work with a secondary trading marketplace like Nasdaq Private Market.
Learn more about the secondary market for private company shares on the investors page.
Thymmune Therapeutics Stock does not trade on public stock exchanges. In order to sell Thymmune Therapeutics shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors.
Learn more about NPM services for selling privately held stock on the Employee Shareholders page.
Read more about how to sell private company stock on the private secondary market:
Thymmune Therapeutics does not have a publicly available stock price because it is privately held and not traded on public stock exchanges. Through the NPM Data and Intelligence database from Nasdaq Private Market, you can view Thymmune Therapeutics share price and other valuable private market data.
Read more about secondary market private company stock prices:
There is no ticker symbol for Thymmune Therapeutics stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company ‘street’ name or legal name.
Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell Thymmune Therapeutics stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.
Learn more about selling privately held stock on the Employee Shareholders page.
Read more about how to sell shares of a private company and eligibility for selling privately held stock:
Currently, Nasdaq Private Market only works with accredited entities and institutional investors to purchase private company stock. In order to invest in Thymmune Therapeutics stock, you need to be an accredited entity or institutional investor.
Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.
Once you buy or sell, stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.
Thymmune Therapeutics is a private company and has not had an IPO. There is currently no Thymmune Therapeutics IPO price. Get started to begin exploring the Nasdaq Private Market Data and Intelligence database and gain access to actionable data related to Thymmune Therapeutics IPO.
Learn more about Data and Intelligence private company stock data for institutional investors on the on the NPM Data and Intelligence Product Page.
